Related Experiment Video

Updated: Apr 4, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Managing acquired resistance in EGFR-mutated non-small cell lung cancer

Patrick M Forde1, David S Ettinger1

  • 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Clinical Advances in Hematology & Oncology : H&O
|September 10, 2015
PubMed

Insights

First-line EGFR TKIs are effective for advanced EGFR-mutated non-small cell lung cancer but resistance develops. This review covers new strategies to overcome acquired resistance, including third-generation TKIs and novel agents.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate efficacy in advanced EGFR-mutated non-small cell lung cancer.
  • Acquired resistance to first-generation EGFR TKIs is a significant clinical challenge, limiting long-term patient benefit.
  • Current standard treatment for acquired resistance is cytotoxic chemotherapy, which has limitations.

Purpose of the Study:

  • To review emerging strategies for overcoming acquired resistance to EGFR TKI therapy.
  • To highlight novel therapeutic agents and approaches targeting resistance mechanisms.
  • To provide an overview of the latest research in EGFR TKI resistance.

Main Methods:

  • Literature review of recent preclinical and clinical studies.
  • Focus on third-generation EGFR TKIs targeting specific resistance mutations.
  • Exploration of other novel therapeutic agents and combination strategies.

Main Results:

  • Third-generation EGFR TKIs show promise in targeting the T790M resistance mutation.
  • Various novel agents and combination therapies are under investigation to overcome resistance.
  • Understanding resistance mechanisms is crucial for developing effective treatments.

Conclusions:

  • Acquired resistance to EGFR TKIs remains a critical hurdle in non-small cell lung cancer treatment.
  • Novel therapeutic strategies, including next-generation TKIs and other agents, are essential for improving patient outcomes.
  • Continued research is vital to develop more durable and effective therapies for EGFR-mutated NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K